# Study of ALXN2050 in Participants With Hepatic Impairment

> **NCT05259085** · PHASE1 · TERMINATED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 26 (actual)

## Conditions studied

- Impaired Hepatic Function
- Healthy

## Interventions

- **DRUG:** ALXN2050

## Key facts

- **NCT ID:** NCT05259085
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-07
- **Primary completion:** 2024-08-12
- **Final completion:** 2024-08-12
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** Sponsor decision.
- **Last updated:** 2025-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05259085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05259085, "Study of ALXN2050 in Participants With Hepatic Impairment". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05259085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*